Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025
Cash, cash equivalents and short-term investments of
Webcast to be held today,
“As the obesity therapeutics space evolves, increasing attention is being placed on agents that are able to drive weight loss while addressing the quality of that weight loss and the comorbidities of obesity. With significant weight loss, preservation of lean mass and reductions in serum lipids and liver fat achieved in our clinical trials, we believe that pemvidutide could differentiate itself from other therapies in this competitive market. With these promising data, we are preparing for our End-of-Phase 2 meeting with the
Recent Highlights and Anticipated Milestones:
- In
March 2024 , Altimmune reported additional data from the Phase 2 MOMENTUM trial of pemvidutide in obesity, demonstrating significant weight loss with class-leading preservation of lean mass- Body composition analysis from MOMENTUM showed 74.5% of weight loss came from body fat and only 25.5% of weight loss came from lean mass in pemvidutide-treated subjects.
- This analysis demonstrated a preferential reduction of visceral over subcutaneous fat in the pemvidutide group.
- Analyses of the MOMENTUM body composition and other new data to be presented at scientific meetings later this year.
- Preparations underway for an End-of-Phase 2 meeting with FDA
- The Company plans to present a comprehensive data package, including data from the MOMENTUM Phase 2 trial of pemvidutide in obesity.
- The meeting is currently expected to take place in late Q3 2024.
- The Company has continued to advance enrollment in IMPACT, a biopsy-driven Phase 2b trial of pemvidutide in MASH
- The Company expects to enroll approximately 190 subjects with and without diabetes, randomized to receive one of two doses of pemvidutide or placebo.
- The primary efficacy measures of the trial are MASH resolution or fibrosis improvement with topline data expected in Q1 2025.
- The primary efficacy readout will be at 24 weeks of treatment, which is the earliest time point for any incretin-based therapy in MASH.
Financial Results for the Three Months Ended
- Altimmune had cash, cash equivalents and short-term investments totaling
$182.1 million atMarch 31, 2024 . - Research and development expenses were
$21.5 million for the three months endedMarch 31, 2024 , compared to$17.2 million in the same period in 2023. The expenses for the quarter endedMarch 31, 2024 included$13.5 million in direct costs related to development activities for pemvidutide and$1.0 million in direct costs related to winddown and closing of our HepTcell program as announced onMarch 27, 2024 . - General and administrative expenses were
$5.3 million for the three months endedMarch 31, 2024 , compared to$4.5 million in the same period in 2023. The increase was primarily due to a$0.6 million increase in stock compensation and other labor related expenses. - Interest income for the three months ended
March 31, 2024 was$2.4 million as compared to$1.7 million in the same period in 2023, primarily due to an increase in interest income earned on cash equivalents and short-term investments. - Net loss for the three months ended
March 31, 2024 was$24.4 million , or$0.34 net loss per share, compared to a net loss of$20.1 million , or$0.40 net loss per share, in the same period in 2023.
Conference Call Information:
| Date: | |
| Time: | |
| Webcast: | To listen, the conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. |
| Dial-in: | To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call. |
Following the conclusion of the call, the webcast will be available for replay on the Investor Relations (IR) page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, leading to rapid reductions in levels of liver fat and serum lipids. In clinical trials, once-weekly pemvidutide has shown compelling weight loss, robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure with a clean safety profile to date. The
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to
Investor Contact:
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Phone: 646-382-3403
lroth@burnsmc.com
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
CONSOLIDATED BALANCE SHEETS (In thousands, except share and per-share amounts) |
||||||||
| 2024 | 2023 |
|||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 78,978 | $ | 135,117 | ||||
| Restricted cash | 41 | 41 | ||||||
| Total cash, cash equivalents and restricted cash | 79,019 | 135,158 | ||||||
| Short-term investments | 103,046 | 62,698 | ||||||
| Accounts and other receivables | 307 | 1,111 | ||||||
| Income tax and R&D incentive receivables | 2,272 | 3,742 | ||||||
| Prepaid expenses and other current assets | 2,871 | 6,917 | ||||||
| Total current assets | 187,515 | 209,626 | ||||||
| Property and equipment, net | 544 | 651 | ||||||
| Other assets | 299 | 363 | ||||||
| Total assets | $ | 188,358 | $ | 210,640 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,760 | $ | 2,070 | ||||
| Accrued expenses and other current liabilities | 7,573 | 10,073 | ||||||
| Total current liabilities | 11,333 | 12,143 | ||||||
| Noncurrent liabilities | 4,088 | 4,398 | ||||||
| Total liabilities | 15,421 | 16,541 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, |
7 | 7 | ||||||
| Additional paid-in capital | 668,816 | 665,427 | ||||||
| Accumulated deficit | (490,725 | ) | (466,331 | ) | ||||
| Accumulated other comprehensive loss, net | (5,161 | ) | (5,004 | ) | ||||
| Total stockholders’ equity | 172,937 | 194,099 | ||||||
| Total liabilities and stockholders’ equity | $ | 188,358 | $ | 210,640 | ||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per-share amounts) |
||||||||
| Three Months Ended | ||||||||
| 2024 |
2023 |
|||||||
| Revenues | $ | 5 | $ | 21 | ||||
| Operating expenses: | ||||||||
| Research and development | 21,487 | 17,249 | ||||||
| General and administrative | 5,312 | 4,531 | ||||||
| Total operating expenses | 26,799 | 21,780 | ||||||
| Loss from operations | (26,794 | ) | (21,759 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (1 | ) | (2 | ) | ||||
| Interest income | 2,413 | 1,668 | ||||||
| Other income (expense), net | (12 | ) | 19 | |||||
| Total other income (expense), net | 2,400 | 1,685 | ||||||
| Net loss | (24,394 | ) | (20,074 | ) | ||||
| Other comprehensive income — unrealized (loss) gain on short-term investments | (157 | ) | 126 | |||||
| Comprehensive loss | $ | (24,551 | ) | $ | (19,948 | ) | ||
| Net loss per share, basic and diluted | $ | (0.34 | ) | $ | (0.40 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 70,801,713 | 50,125,685 | ||||||
Source: Altimmune, Inc
